impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs

1, 2, 3, 4, 5

 

  1. Division of Rheumatology and Clinical Immunology, The University of Hong Kong, China.
  2. Division of Rheumatology and Clinical Immunology, The University of Hong Kong, China.
  3. Division of Rheumatology and Clinical Immunology, The University of Hong Kong, China.
  4. Division of Medical Oncology, The University of Hong Kong, China.
  5. Division of Rheumatology and Clinical Immunology, The University of Hong Kong, China. cslau@hku.hk

CER14502
2022 Vol.40, N°5
PI 0913, PF 0920
Full Papers

purchase article

PMID: 34369368 [PubMed]

Received: 07/02/2021
Accepted : 19/04/2021
In Press: 24/07/2021
Published: 11/05/2022

Abstract

OBJECTIVES:
To determine the risk of 6 types of malignancies in spondyloarthritis (SpA) with and without psoriasis (PsO) and on disease-modifying anti-rheumatic drugs (DMARDs), compared to non-specific back pain (NSBP).
METHODS:
Medical records were retrieved. Patients with SpA with and without PsO were identified and compared to those with NSBP. Clinical data; follow-up duration; comorbidities; dates and types of cancer diagnosed; types and duration of DMARD therapy were collected. Propensity score adjustment was used to compare the risks of malignancies between SpA, SpA with and without PsO, and NSBP. Cox regression analysis was used to determine the risk of malignancy in DMARD therapy.
RESULTS:
A total of 3020 patients with SpA and 2527 patients with NSBP were studied. The mean follow-up duration in patients with SpA and NSBP was 9.6 years and 13.5 years respectively. Incidence and risk of malignancies were compatible between SpA and NSBP. The incidences of various carcinomas (per 1000 patient-years) in SpA were: 1.37 for colorectal carcinoma; 0.30 for carcinoma of pancreas; 0.30 for carcinoma of stomach; and 0.91 for lymphomas. Risk of colorectal carcinoma (HR 2.46; p=0.03) and lymphomas (HR 2.86; p=0.04) was increased in SpA with concomitant PsO. DMARD therapy was not associated with increased risks of malignancies after adjustment for confounding factors.
CONCLUSIONS:
Risk of malignancy was increased in SpA with PsO but not in other subtypes of SpA or DMARD therapy.

DOI: https://doi.org/10.55563/clinexprheumatol/o3rgv1

Rheumatology Article

Rheumatology Addendum